Observational studyNature communications2021
Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections.
Observational study in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Adaptive immunity to SARS-CoV-2 infection: A systematic review.Frontiers in immunology · 2022Pooled it
- Reduced cytokine levels among people living with HIV (PLWH) in ghana co-infected with human coronaviruses.Scientific reports · 2026Article
- IL-19 Modulates Antiviral Immunity and Inflammation via IL-20RB/STAT3/TRIM22 Signaling Pathway.Journal of medical virology · 2026Article
- Comparative single-cell immune responses in peripheral blood and lymph node of immunized SARS-CoV-2 challenged infant rhesus macaques.Frontiers in immunology · 2025Article
- Effect of colony‑stimulating factor in the mechanism of bone metastasis development (Review).Oncology reports · 2024Review
- Adenosine deaminase 2 regulates the activation of the toll-like receptor 9 in response to nucleic acids.Frontiers of medicine · 2024Article
- Article
- In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Multi-cohort study on cytokine and chemokine profiles in the progression of COVID-19.Scientific reports · 2024Article
- E3 ubiquitin ligase RNF128 negatively regulates the IL-3/STAT5 signaling pathway by facilitating K27-linked polyubiquitination of IL-3Rα.Cell communication and signaling : CCS · 2024Article
- The role of dendritic cells in respiratory viral infection.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- PD-L1- and IL-4-expressing basophils promote pathogenic accumulation of T follicular helper cells in lupus.Nature communications · 2024Article
- Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung.Frontiers in immunology · 2024Article
- IL-3: key orchestrator of inflammation.Frontiers in immunology · 2024Review
- Aloe-emodin plus TIENAM ameliorate cecal ligation and puncture-induced sepsis in mice by attenuating inflammation and modulating microbiota.Frontiers in microbiology · 2024Article
- RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.The Journal of clinical investigation · 2023Article
- Proteolytic inactivation of CXCL12 in the lungs and circulation of COVID-19 patients.Cellular and molecular life sciences : CMLS · 2023Article
- Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease.Communications medicine · 2023Article
- Biological function of resveratrol and its application in animal production: a review.Journal of animal science and biotechnology · 2023Review
- Association of Interleukin-32 and Interleukin-34 with Cardiovascular Disease and Short-Term Mortality in COVID-19.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. In a prospective multicentric study, we identify IL-3 as an independent prognostic marker for the outcome during SARS-CoV-2 infections. Specifically, low plasma IL-3 levels is associated with increased severity, viral load, and mortality during SARS-CoV-2 infections. Patients with severe COVID-19 exhibit also reduced circulating plasmacytoid dendritic cells (pDCs) and low plasma IFNα and IFNλ levels when compared to non-severe COVID-19 patients. In a mouse model of pulmonary HSV-1 infection, treatment with recombinant IL-3 reduces viral load and mortality. Mechanistically, IL-3 increases innate antiviral immunity by promoting the recruitment of circulating pDCs into the airways by stimulating CXCL12 secretion from pulmonary CD123
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.